Lundbeck has ended its bidding war with Alkermes to acquire Avadel Pharmaceuticals, saying that it will not increase its offer for the sleep disorder drug developer beyond the approximately $2.4 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback